A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes
- Registration Number
- NCT01044017
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This randomized, double-blind, placebo-controlled, cross-over study will evaluate the glucose concentration and other glycemic parameters of efficacy, and the safety and tolerability and pharmacokinetics of single oral doses of RO4998452 in patients with diabetes mellitus type 2. On 3 treatment days a week apart, patients will each receive orally one of 2 dose levels of RO4998452 or placebo. Anticipated time of study treatment is 3 weeks. Target sample size is \<50.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- Adult patients, 18-75 years of age
- Type 2 diabetes mellitus, diagnosed for at least 3 months at screening
- Treatment with diet and exercise
- BMI between 27 and 40 kg/m2
Exclusion Criteria
- Type 1 diabetes
- History of ketoacidosis, hyperosmolar coma, or lactic acidosis
- Renal disease or renal dysfunction
- Evidence of significant diabetic complication
- Currently or within 3 months prior to screening treated with any oral or injectable anti-diabetic agents (exception: insulin injection in emergency situation)
- History of anti-diabetic triple therapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description A RO4998452 - B RO4998452 - C Placebo -
- Primary Outcome Measures
Name Time Method Effect on postprandial plasma glucose concentration Following meal 13 hours after dosing
- Secondary Outcome Measures
Name Time Method Mean postprandial daily plasma glucose concentration (3 consecutive meals) 25 hours Mean daily blood glucose concentration, pre-meal plasma glucose concentration, plasma insulin concentration Assessments up to 25 hours after dosing Safety and tolerability: AEs, laboratory parameters AEs throughout study, laboratory assessments on 3 treatment days and on follow-up Urinary glucose excretion Assessments up to 25 hours after dosing